Key studies that have changed the history and treatment of early HER2+ breast cancer: focus on individual therapy
HER2-positive breast cancer is a unique subtype of the disease, not only in terms of aggressive biology, but also in terms of treatment options. Over the past 15 years, the strategy for treating early HER2-positive breast cancer has undergone a real evolution – from the absence of anti-HER2 therapy...
Saved in:
| Main Authors: | I. V. Kolyadina, I. V. Poddubnaya |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2021-01-01
|
| Series: | Опухоли женской репродуктивной системы |
| Subjects: | |
| Online Access: | https://ojrs.abvpress.ru/ojrs/article/view/766 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Switching to T-DM1 remains justified in patients with HER2-negative residual invasive breast cancer after neoadjuvant therapy
by: Charles E. Geyer, Jr., et al.
Published: (2025-06-01) -
Detection of serum HER2 in patients treated with neratinib or trastuzumab: analysis of the I-SPY Trial
by: Mark Hensley, et al.
Published: (2025-07-01) -
Evaluation of Treatment and Recurrence-Free Survival in Patients with Early HER2-Positive Breast Cancer: Real-Life Data Comparing Public and Private Healthcare
by: Mariana Pilon Capella, et al.
Published: (2024-01-01) -
De-escalated neoadjuvant nab-paclitaxel combined with pyrotinib and trastuzumab in intrinsic HER2-enriched breast cancer (NJMU-BC01): a multicenter, single-arm, phase 2 trialResearch in context
by: Hong Pan, et al.
Published: (2025-08-01) -
Current approaches to the treatment of HER2‑positive breast cancer with brain metastases
by: T. Yu. Semiglazova, et al.
Published: (2021-06-01)